Research programme: microbial therapeutics - Vedanta Biosciences

Drug Profile

Research programme: microbial therapeutics - Vedanta Biosciences

Alternative Names: Microbiome-based therapeutics - Vedanta; VE 800

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vedanta Biosciences
  • Developer NYU Langone Medical Center; Vedanta Biosciences
  • Class Anti-infectives; Anti-inflammatories; Antineoplastics; Immunotherapies
  • Mechanism of Action Helper-inducer T-lymphocyte stimulants; Immunomodulators; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Autoimmune disorders

Most Recent Events

  • 13 Dec 2017 The United States Patent and Trademark Office issues four new patents for microbial therapeutics
  • 29 Nov 2017 Vedanta Biosciences enters into collaborations with the Leiden University Medical Center and the University of South Alabama to develop microbiome therapeutics for Cancer
  • 29 Nov 2017 Vedanta Biosciences expands collaboration with the NYU Langone Medical Center to include development of microbiome therapies for Bladder cancer and Lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top